Melanoma has served as the test bed for ICI with the initial development of anti-CTLA-4 antibodies (ipilimumab) (30) and more recently antibodies that inhibit the programmed death-1 axis (e.g., nivolumab, pembrolizumab) (31, 32). Here, CTLA4 is linked to melanoma.